Launch week offerEnds in00h00m00s

annual Promonthly Pro

Surein Arulananda

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (15)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (10)

Ilariya Tarasova

University of Melbourne

AUSTRALIA

View details

Daniel Garama

Principal Investigator - NG-PDT Program

MONASH UNIVERSITY

AUSTRALIA

View details

Sue Evans

Professor

MONASH UNIVERSITY

AUSTRALIA

View details

Dayna Leah Swiatek

Associate Professor, Cancer Equity Program Lead, Monash Partners Comprehensive Cancer Consortium

MONASH UNIVERSITY

AUSTRALIA

View details

Kenneth O'Byrne

Queensland University of Technology

AUSTRALIA

View details

Prepare your application

Review drafts before you send them.

Surein Arulananda

Research Interests

Make your next move.

Explore related searches

Articles (15)

Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy

Evaluation of a co-designed nurse-led geriatric oncology multidisciplinary model in treatment-naive older adults with solid cancers.

Immune Doublet Checkpoint Inhibition in <i>EGFR</i>-Mutated NSCLC: A Fire That Fails to Illuminate the Orchard

Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis

LuSato-1: Phase I study of <SUP>177</SUP>Lu-SSO110 with <SUP>68</SUP>Ga-SSO120 companion imaging in patients with extensive stage small cell lung cancer (ES-SCLC) on maintenance treatment with immune checkpoint inhibition (ICI).

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.

ImpACT Project: Improving Access to Clinical Trials in Victoria, an Artificial Intelligence–Based Approach

Effect of CVA21, an Oncolytic Virus, in combination with Pembrolizumab on immunogenicity and the tumour microenvironment in advanced NSCLC: a phase I/II trial

Advances in Lung Cancer Basic and Translational Research in 2025-Overview and Perspectives Focusing on NSCLC

Illuminating mesothelioma immune microenvironment in response to immune checkpoint inhibitors using spatial transcriptomics

The OPEN trial-from the darkness, comes light

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.

Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion.

Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?

Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report

Collaborators (10)

Ilariya Tarasova

Daniel Garama

Sue Evans

Dayna Leah Swiatek

Kenneth O'Byrne

Daniel Gough

Sandra Ortiz-Cuaran

Benjamin Solomon

Chee Khoon Lee

Atul Malhotra

Make your next move.